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I M M U N O L O G Y
cAMP metabolism controls caspase-11 inflammasome 
activation and pyroptosis in sepsis
Ruochan Chen1,2, Ling Zeng3, Shan Zhu1,4, Jiao Liu1, Herbert J. Zeh5, Guido Kroemer6,7,8,9,10,11,12, 
Haichao Wang13, Timothy R. Billiar14, Jianxin Jiang3*, Daolin Tang1,5*, Rui Kang5*
The ability of cytosolic lipopolysaccharide (LPS) to activate caspase-11–dependent nonclassical inflammasome 
is intricately controlled to avoid excessive inflammatory responses. However, very little is known about the regu-
latory role of various metabolic pathways in the control of caspase-11 activation. Here, we demonstrate that 
l-adrenaline can act on receptor ADRA2B to inhibit the activation of the caspase-11 inflammasome by cytosolic 
LPS or Escherichia coli infection in macrophages. l-adrenaline–induced cAMP production via the enzyme ADCY4 
promotes protein kinase A (PKA) activation, which then blocks the caspase-11–mediated proteolytic maturation 
of interleukin-1, gasdermin D (GSDMD) cleavage, and consequent DAMP release. Inhibition of PDE8A-mediated 
cAMP hydrolysis limits caspase-11 inflammasome activation and pyroptosis in macrophages. Consequently, 
pharmacological modulation of the ADRA2B-ADCY4-PDE8A-PKA axis, knockout of caspase-11 (Casp11−/−), or Gsdmd 
inactivation (GsdmdI105N/I105N) similarly protects against LPS-induced lethality in poly(I:C)-primed mice. Our results 
provide previously unidentified mechanistic insight into immune regulation by cAMP and represent a proof of 
concept that immunometabolism constitutes a potential therapeutic target in sepsis.
INTRODUCTION
Macrophages are innate immune cells that play a key role in initia-
tion, amplification, and resolution of inflammatory processes. As an 
inflammatory cell death pathway, pyroptosis occurs mainly in mac-
rophages and their precursors, monocytes following activation of 
inflammatory caspase-1 and caspase-11 (caspase-4 and caspase-5 in 
humans), and cleavage-mediated activation of GSDMD (gasdermin D) 
(1, 2). The resultant N-terminal GSDMD fragment, GSDMD-N, oligo-
merizes to form pores in the plasma membrane, resulting in its perme-
abilization and lytic cell death (1–4). Thus, inflammasomes not only 
mediate proteolytic processing and secretion of IL-1 (interleukin-1) 
family cytokines (e.g., IL-1 and IL-18) but also cause the cell death–
associated release of damage-associated molecular patterns [e.g., LDH 
(lactate dehydrogenase) and HMGB1 (high-mobility group box 1)]. 
Excessive activation of inflammasomes and consequent pyroptosis are 
implicated in human diseases and conditions, including sepsis (5).
Sepsis from microbial infection remains a prominent cause of death 
of critically ill patients in the intensive care unit. Lipopolysaccharide 
(LPS) is a component of the outer membrane of Gram-negative 
bacteria, one of the leading pathogens responsible for sepsis. LPS ini-
tiates immediate innate immune responses not only through cell sur-
face TLR4 (Toll-like receptor 4) to induce inflammation-related 
gene expression (6) but also via the activation of a cytosolic receptor, 
caspase-11, to trigger nonclassical inflammasome activation (7–11). 
Cytosolic LPS can cause caspase-11 oligomerization and inflammasome 
activation, leading to the generation of GSDMD-N and subsequent 
pyroptosis in macrophages (11). Mice genetically deficient in caspase-11, 
but not caspase-1, are resistant to LPS-induced septic shock (7, 10, 12). 
This cytosolic LPS–caspase-11–sensing pathway represents not only a 
important paradigm in innate immunity but also a potential target for 
therapeutic exploration in sepsis. However, the metabolic regulation 
of the caspase-11 inflammasome has not been elucidated.
Cyclic adenosine monophosphate (cAMP) is one of the principal sec-
ond messengers generated in response to hormones and acts intracel-
lularly by activating its effectors PKA (protein kinase A) and RAPGEF3/
EPAC (rap guanine nucleotide exchange factor 3). cAMP is synthe-
sized from adenosine triphosphate by enzymes from the ADCY 
(adenylyl cyclase) family and can be hydrolyzed by a series of enzymes 
from the phosphodiesterase (PDE) family (13). In this study, we provide 
evidence that the surge in intracellular cAMP stimulated by the stress 
hormone and neurotransmitter l-adrenaline–induced cAMP can con-
trol cytosolic LPS-induced activation of the caspase-11 inflamma some 
and consequent pyroptosis in macrophages. Targeting the ADCY4- 
PDE8A-PKA axis protects mice from caspase-11–dependent septic death. 
Our data therefore shed previously unidentified mechanistic insight into 
the metabolic modulation of the caspase-11 inflammasome and provide 
a potential therapeutic strategy for the treatment of lethal infection.
RESULTS
Identification of l-adrenaline as an inhibitor of the 
caspase-11 inflammasome
Activation of the caspase-11–dependent noncanonical inflammasome 
requires two signals: a priming signal (e.g., TLR ligands) that induces 
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the transcriptional up-regulation of inflammasome components and 
then a sensing signal (e.g., LPS electroporation or Escherichia coli infec-
tion) that triggers caspase-11 activation and pyroptosis (7–10, 12). To 
identify potential regulators of caspase-11 inflammasome in innate 
immune cells, we screened a U.S. Food and Drug Administration 
(FDA)–approved library of 1018 drugs in murine bone marrow–
derived macrophages (BMDMs) that were first primed by exposure 
to extracellular LPS and then electroporated with LPS (LPSe). The 
LPSe-induced cell growth inhibition was reversed by certain drugs 
(Fig. 1A). The top five drugs that counteracted LPSe-induced growth 
inhibition in LPS-primed BMDMs included l-adrenaline (a stress 
hormone, also termed epinephrine), levosulpiride (an antipsychotic 
agent), tetracaine (a local anesthetic), prednisolone (a synthetic 
glucocorticoid), and quinapril (an angiotensin-converting enzyme 
inhibitor) (Fig. 1B). These drugs also prevented LPSe-induced cell 
death in the human monocytic cell line, THP1 (Fig. 1B). LDH and 
IL-1 release assay indicated that LPSe-induced cell death and cyto-
kine release in BMDMs and THP1 cells were blocked by these top 
five drugs (Fig. 1B). l-adrenaline was also active when it was tested 
on BMDMs that were primed with Pam3CSK4 (a TLR1 and TLR2 
ligand) or poly(I:C) (a TLR3 ligand) instead of LPS. Irrespective of 
the priming signal, l-adrenaline inhibited the cytotoxicity and IL-1 
release of LPSe or E. coli infection (Fig. 1C). Similar to BMDMs and 
THP1 cells, l-adrenaline also inhibited LPSe-induced cytotoxicity and 
IL-1 release in human primary monocytes (fig. S1). Immunoblot 
analysis showed that l-adrenaline also inhibited the LPSe- or E. coli–
induced caspase-11 activation (yielding a p26 band), GSDMD-N for-
mation, and proteolytic IL-1 maturation (yielding a p17 fragment) 
in LPS-primed BMDMs (Fig. 1D). As expected, caspase-11 and 
GSDMD, but not canonical inflammasome proteins [e.g., NLRP3 
(NLR family pyrin domain containing 3), NLRC4 (NLR family CARD 
domain containing 4), and NLRP1], were required for the killing of 
LPS-primed BMDMs by LPSe or E. coli (Fig. 1E). l-adrenaline failed 
to affect LPS-induced pro–caspase-11 and pro–IL-1 expression 
during the priming stage of inflammasome activation (fig. S2). 
Collectively, these findings suggest that l-adrenaline acts as an in-
hibitor of caspase-11 inflammasome activation in macrophages and 
monocytes.
Adrenoceptor a 2B is required for l-adrenaline–mediated 
blockade of caspase-11 inflammasome activation
The adrenergic receptors are a class of G protein (heterotrimeric 
GTP-binding protein)–coupled receptors for endogenous cate-
cholamines, including l-adrenaline. To identify the adrenergic 
receptor responsible for l-adrenaline–mediated inhibition of 
caspase-11 inflammasome activation, we first analyzed adrenergic 
receptor expression in activated innate immune cells. Quantitative 
real-time polymerase chain reaction (qPCR) analysis showed that 
the mRNA expression of adrenoceptor a 2B (Adra2B), but not that 
of other adrenergic receptors (Adrb1, Adrb2, Adrb3, Adra2a, 
Adra2c, Adra1a, Adra1b, or Adra1d), was up- regulated in BMDMs 
in response to LPSe combined with l-adrenaline (Fig.  2A). 
Knockdown of Adra2b (but not Adra2a) by small interfering RNA 
(siRNA) pools (Fig. 2B) reversed the l-adrenaline– mediated inhi-
bition of LDH and IL-1 release from BMDMS responding to LPSe 
or E. coli (Fig.  2C). Western blot analysis confirmed that Adra2b 
knockdown abrogated the inhibitory effect of l-adrenaline on LPSe- 
induced caspase-11 (p26) activation, GSDMD-N formation, and pro-
teolytic IL-1 maturation (p17) (Fig. 2D). These findings suggest that 
ADRA2B mediates l-adrenaline activity to counter-regulate the cyto-
plasmic LPS-mediated caspase-11 activation and pyroptosis.
ADCY4-mediated cAMP synthesis inhibits caspase-11 
inflammasome activation
l-adrenaline acts as the “flight or fight hormone” in response to stress 
and promotes rapid, close-to-immediate rises in intracellular cAMP, 
a process that acts as the major molecular mechanism of signal trans-
duction. As predicted, l-adrenaline increased cAMP levels in BMDMs 
responding to LPSe or E. coli (Fig. 3A). Knockdown of Adra2b (but not 
Adra2a) suppressed this l-adrenaline–elicited cAMP elevation, con-
firming that ADRA2B mediates the l-adrenaline effects on this system 
(Fig. 3A). To evaluate the regulatory role of cAMP on LPSe-induced 
caspase-11 activation, we used cell-permeable cAMP analogs. Several 
cAMP analogs such as 8-bromoadenosine–3′,5′-cyclic monophosphate 
sodium salt (8-Br-cAMP) and N6-benzoyladenosine–3′,5′-cyclic 
monophosphate sodium salt (6-Bn-cAMP) similarly inhibited LPSe- or 
E. coli–induced LDH and IL-1 release from BMDMs and THP1 cells 
(Fig. 3B). The LPSe-induced caspase-11 (p26) activation, GSDMD-N 
formation, and proteolytic IL-1 maturation (p17) were also inhib-
ited by 8-Br-cAMP or 6-Bn-cAMP (Fig. 3C). These findings suggest 
that cAMP can act as an endogenous inhibitor of caspase-11–mediated 
inflammasome activation.
The synthesis of cAMP elicited by hormone-receptor interactions 
requires the enzymatic activity of proteins from the ADCY. There 
are 10 ADCY family members in mammalian cells. qPCR analysis 
showed that the mRNA expression of Adcy4, but not any other ADCY 
members, was up-regulated in BMDMs responding to LPSe com-
bined with l-adrenaline (Fig. 3D). Notably, knockdown of Adcy4 
(but not Adcy2) expression (Fig. 3E) blocked cAMP production and 
restored the LDH and IL-1 release in response to LPSe or E. coli 
combined with l-adrenaline (Fig. 3F). Immunoblot revealed that 
LPSe-induced and caspase-11 (p26) activation, GSDMD-N formation, 
and proteolytic IL-1 maturation (p17) were not inhibited any more 
by l-adrenaline in LPS-primed BMDMs when Adcy4 was depleted 
(Fig. 3G). It thus appears that ADCY4 is required for l-adrenaline–
induced cAMP synthesis to limit cytosolic LPS-induced caspase-11 
inflammasome activation and pyroptosis.
PDE8A-mediated cAMP hydrolysis promotes activation of 
the caspase-11 inflammasome
To further define the role of cAMP metabolism in caspase-11 in-
flammasome activation, we investigated the impact of cAMP hydrol-
ysis on cytosolic LPS-induced pyroptosis. PDEs are the only enzymes 
known to degrade cAMP and cGMP (guanosine 3′,5′-monophosphate) 
in mammalian cells (13). One hundred members of the PDE super-
family are divided into 11 subfamilies. Among them, PDE4 (PDE4A-D), 
PDE7 (PDE7A and PDE7B), and PDE8 (PDE8A and PDE8B) are 
cAMP-selective hydrolases. LPSe increased Pde8a mRNA expression, 
whereas l-adrenaline inhibited this process (Fig. 4A). In contrast, other 
mRNAs of cAMP-selective hydrolases—including Pde4a, Pde4b, 
Pde4c, Pde4d, Pde7a, Pde7b, and Pde8b—were not notably altered by 
LPSe combined with l-adrenaline (Fig. 4A), pointing to a specific role 
of PDE8A in the control of cAMP hydrolysis.
To determine the potential relationship between PDE8A and cAMP 
in the regulation of caspase-11–mediated inflammasome activation, 
we first added PF-04957325, a PDE8-selective inhibitor, to BMDMs 
and THP1 cells. Administration of PF-04957325 increased cAMP 
levels and inhibited LDH and IL-1 release in response to LPSe or 
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Fig. 1. Identification of l-adrenaline as a caspase-11 inflammasome inhibitor. (A) Heatmap of cell viability changes in LPS-primed BMDMs after LPS electroporation 
(1 g, 16 hours) in the absence or presence of 1018 FDA-approved drugs (10 M). (B) Analysis of cell viability, LDH release, and IL-1 release in LPS-primed BMDMs or THP1 
cells after LPS electroporation (1 g, 16 hours) in the absence or presence of indicated drugs (10 M). n = 3, data expressed as means ± SD; *P < 0.05 versus LPS electropo-
ration group, t test. (C) Analysis of LDH and IL-1 release in LPS-, poly(I:C)-, or Pam3CSK4-primed BMDMs after LPS electroporation (1 g, 16 hours) or E. coli [multiplicity of 
infection (MOI), 25; 16 hours] infection in the absence or presence of l-adrenaline (10 M). n = 3, data expressed as means ± SD; *P < 0.05, t test. (D) Western blot analysis 
of indicated proteins in the supernatant (SN) or cell lysate in LPS-primed BMDMs after LPS electroporation (1 g, 16 hours) or E. coli (MOI, 25; 16 hours) infection in the 
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E. coli (Fig. 4B). Knockdown of Pde8a, but not Pde8b, (Fig. 4C) also 
increased the intracellular cAMP levels and inhibited LDH and 
IL-1 release in response to LPSe or E. coli (Fig. 4D). These findings, 
combined with Western blot analysis to assess the activation of 
caspase-11 (p26) and the generation of its products GSDMD-N and 
proteolytically mature IL-1 (p17) (Fig. 4E), indicate that PDE8A is 
a positive regulator of cytosolic LPS-induced pyroptosis.
PKA negatively regulates caspase-11  
inflammasome activation
To further explore the mechanism of cAMP control of caspase-11 
inflammasome activation, we measured the activity of PKA, which 
is known as a classical cAMP-responsive enzyme (14). PKA activity 
was down-regulated in BMDMs and THP1 cells in response to LPSe 
or E. coli infection. In contrast, PKA activity was restored upon treat-
ment with l-adrenaline, 8-Br-cAMP, 6-Bn-cAMP, or PF-04957325 
(Fig. 5A). In addition, knockdown of Adra2b or Adcy4 reversed the 
positive effect of l-adrenaline on PKA activity in this system (Fig. 5B), 
supporting the idea that ADRA2B-ADCY4-PDE8A–dependent cAMP 
metabolism pathway controls the PKA activity.
Upon binding of cAMP to PKA regulatory subunits, the catalytic 
subunits are released as active monomers (14). To evaluate the role 
of PKA in the regulation of cytosolic LPS-induced inflammasome 
activation and pyroptosis, we pharmacologically inhibited PKA with 
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Rp-8-CPT-cAMPs or depleted its catalytic subunit a (Prkaca) and 
 (Prkacb) with suitable siRNAs (Fig. 5C). Inhibition of PKA increased 
the LPSe-induced LDH and IL-1 release; this process was reversed by 
pan-caspase inhibitor Z-VAD-FMK but not by l-adrenaline (Fig. 5D). 
In contrast, the selective RAPGEF3 activator 8-pCPT-2-O-Me-
cAMP-AM had no effect on LPSe-induced LDH and IL-1 release 
with or without knockdown of Prkaca/b (Fig. 5E). Moreover, 
LPSe-induced caspase-11 (p26) activation, GSDMD-N formation, and 
proteolytic IL-1 maturation (p17) were increased after inhibition 
of PKA by Rp-8-CPT-cAMPs or knockdown of Prkaca/b (Fig. 5F). 
Immunoprecipitation analysis further found that the activation of 
the cAMP pathway by l-adrenaline, 8-Br-cAMP, or PF-04957325 re-
stored the PRKACA–capase-11 complex formation and caspase-11 
phosphorylation (p-Ser) in response to LPSe (Fig. 5G). These obser-
vations indicate that the phosphorylation and inhibition of caspase-11 
by PKA restrain cytosolic LPS-induced pyroptosis.
Targeting the cAMP metabolism pathway attenuates 
caspase-11–mediated lethal endotoxic shock
We next investigated the relevance of our in vitro findings in a mouse 
model of acute endotoxic shock. We primed mice by intraperitoneal 
injection of poly(I:C) and subsequently challenged them with LPS. 
Consistent with previous reports (1, 7), poly(I:C)-primed Casp11−/− 
mice and GsdmdI105N/I105N mice (which bear a GSDMD cleavage site 
mutation that renders the protein resistant to proteolytic activation 
by caspase-1 or caspase-11) were more resistant to LPS challenge than 
Tlr4−/− mice, supporting the idea that the activation of caspase-11–
mediated GSDMD cleavage (but not TLR4) is essential for cytosolic 
LPS-induced endotoxic shock (Fig. 6A). Using this caspase-11–
dependent sepsis mouse model, we further observed that systemic 
administration of l-adrenaline, 8-Br-cAMP, or PF-04957325 res-
cued poly(I:C)-primed mice from LPS lethality (Fig. 6B). The serum 
levels of organ dysfunction enzymes [e.g., creatine kinase (CK), ala-
nine aminotransferase (ALT), and blood urea nitrogen (BUN)], in-
flammasome cytokines (e.g., IL-1 and IL-18), and pyroptosis markers 
(e.g., LDH and HMGB1) were all reduced in poly(I:C)/LPS-challenged 
mice after treatment with l-adrenaline, 8-Br-cAMP, or PF-04957325 
(Fig. 6C). In contrast, the levels of TNF (tumor necrosis factor) and 
IL-6 were not changed by these inhibitors (Fig. 6C). Increasing cAMP 
synthesis by l-adrenaline and blocking cAMP hydrolysis by the PDE8A 
inhibitor PF-04957325 also elevated serum cAMP levels in mice during 
endotoxic shock (fig. S3). Moreover, acute starvation-induced stress 
increased serum cAMP levels (fig. S4A) and protected against poly(I:C)/
LPS-induced endotoxic shock in mice (fig. S4B). Together, these find-
ings suggest that cAMP metabolism controls caspase-11–mediated 
cytokine release and tissue injury in endotoxic shock.
We also evaluated other top drug candidates from in vitro screen-
ing in an endotoxic shock model. Prednisolone and quinapril, but not 
levosulpiride, increased animal survival in poly(I:C)/LPS-induced 
endotoxic shock (Fig. 6D). Similar to l-adrenaline administration, the 
serum cAMP was up-regulated, whereas CK, BUN, ALT, IL-1, IL-18, 
and LDH were down-regulated by prednisolone and quinapril (Fig. 6E), 
indicating that these drugs use different pathways to increase cAMP 
production in controlling caspase-11–mediated lethal endotoxic shock.
DISCUSSION
Inflammasome formation and activation is a complex process char-
acterized by dynamic changes in molecular assembly and metabolic 
activity. Compared to the canonical caspase-1 inflammasome, the 
more recently identified noncanonical caspase-11 inflammasome re-
mains poorly understood in its mechanistic details and pathophys-
iological implications. In this study, we reveal a role for cAMP in 
counter-regulating caspase-11–dependent inflammasome activation 
in vitro and in vivo. Specifically, several cAMP-relevant receptors, 
enzymes, and effectors—including ADRA2B, ADCY4, PDE8A, and 
PKA—are involved in the control of caspase-11 inflammasome ac-
tivation and pyroptosis (fig. S5). These findings may improve our 
understanding of the metabolic mechanisms involved in the perpet-
uation or resolution of inflammation (15).
The innate immune system detects Gram-negative bacteria partly 
by recognizing LPS, a typical pathogen-associated molecular pattern 
(16). The proposed mechanism of LPS recognition by macrophages 
generally includes two recognition systems. On the cell surface, TLR4 
is required for the detection of extracellular LPS to initiate expres-
sion of a wide array of inflammatory mediators (6). Within the cell, 
caspase-11 acts as an endogenous receptor for the recognition of 
cytosolic LPS to induce pyroptosis (7–11). This combined intra- and 
extracellular action of LPS on macrophages triggers massive immune 
responses that not only facilitate the eradication of infectious patho-
gens but also cause inflammatory injury and endotoxemia if regu-
lated improperly. Given that the application of TLR4 antagonists 
(e.g., Eritoran) for the treatment of patients with sepsis failed in re-
cent clinical trials (17), the caspase-11 pathway has become an attrac-
tive alternative target to treat lethal infectious diseases (18, 19).
In this study, we initially aimed at identifying FDA-approved 
drugs that block caspaspe-11–dependent pyroptosis in macrophages. 
Unexpectedly, one lead candidate that effectively inhibits cytosolic 
LPS-induced pyroptosis in macrophages is l-adrenaline, which is nor-
mally produced by the adrenal glands and certain neurons. Although 
l-adrenaline has been used for long as a vasoactive drug in septic 
shock (20), our current study indicates that the cytosolic LPS-induced 
caspase-11 inflammasome pathway is a previously unidentified target 
of l-adrenaline in macrophages. Among many l-adrenaline receptors 
on the surface of immune cells, we demonstrated that l-adrenaline 
abolishes caspase-11 inflammasome activation via ADRA2B, a  -
adrenergic receptor expressed in various macrophage subtypes (21). 
Dopamine, another vasoactive agent used in sepsis patients, has 
been recently reported to inhibit NLRP3 inflammasome activation 
in macrophages via the dopamine receptor D1 (22). This evidence 
indicates that hormones or neurotransmitters could act as critical 
endogenous modulators of inflammasome activation.
We succeeded in identifying major regulatory hubs connecting 
l-adrenaline stimulation to the blockade of caspase-11 inflammasome. 
cAMP acts as the critical intracellular mediator of l-adrenaline ac-
tivity in the inhibition of caspase-11 inflammasome. cAMP was first 
reported in 1956 as an intracellular second messenger mediating the 
effects of l-adrenaline and glucagon on glycogenolysis in the liver 
tissues (23). In addition to generating hormone-specific effects in 
the nervous system, elevations in cAMP levels also have important 
effects on immune cell differentiation, function, and response to in-
fection (24). Although cAMP exhibits largely inhibitory effects on 
macrophage activation (25, 26), the molecular regulation of cAMP 
metabolism is context dependent. Previous studies showed that 
PDE4B- mediated cAMP hydrolysis mediates extracellular LPS- 
induced TLR4 activation in macrophages (27, 28). Our current find-
ings indicate that ADCY4-mediated cAMP synthesis blocks, whereas 
PDE8A-mediated cAMP hydrolysis promotes, cytosolic LPS-induced 
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Fig. 6. Targeting the cAMP metabolism pathway attenuates caspase-11–mediated lethal endotoxic shock. (A) Survival of indicated mice primed with poly(I:C) 
[10 mg/kg, ip (intraperitoneally)] and then challenged 6 hours (h) later with LPS (2 mg/kg, ip) (n = 10 mice per group; *P < 0.05, Kaplan-Meier survival analysis). (B) Survival 
of indicated mice primed with poly(I:C) (10 mg/kg, ip) and then challenged 6 hours later with LPS (2 mg/kg, ip) in the absence or presence of administration of l-adrenaline 
(2 mg/kg, ip), 8-Br-cAMP (10 mg/kg, ip), or PF-04957325 (5 mg/kg, ip) at −0.5, +12, +24, +36, and +48 hours (n = 10 mice per group; *P < 0.05, Kaplan-Meier survival 
analysis). (C) In parallel to (B), quantitation of indicated serum markers in poly(I:C)-primed mice challenged with LPS in the absence or presence of l-adrenaline, 8-Br-cAMP, 
or PF-04957325 at +3 hours [n = 5 mice per group; *P < 0.05, analysis of variance (ANOVA) least significant difference (LSD) test]. (D) Survival of indicated mice primed with 
poly(I:C) (10 mg/kg, ip) and then challenged 6 hours later with LPS (2 mg/kg, ip) in the absence or presence of administration of prednisolone (5 mg/kg, ip), quinapril 
(30 mg/kg, ip), or levosulpiride (20 mg/kg, ip) at −0.5, +12, +24, +36, and +48 hours (n = 10 mice per group; *P < 0.05, Kaplan-Meier survival analysis). (E) In parallel to (D), 
quantitation of indicated serum markers in poly(I:C)-primed mice challenged with LPS in the absence or presence of prednisolone, quinapril, or levosulpiride at +3 hours 
(n = 5 mice per group; *P < 0.05, ANOVA LSD test).
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caspase-11 inflammasome activation in macrophages. Thus, both the 
synthesis and hydrolysis reactions of cAMP can determine the degree 
of caspase-11 inflammasome activation in macrophages.
We further demonstrated that PKA, but not RAPGEF3, is a major 
cAMP effector to block caspase-11 inflammasome activation in mac-
rophages. PKA is composed of catalytic and regulatory subunits (29). 
In the absence of cAMP, PKA exists in a catalytically inactive form 
bound to the regulatory subunit (29). Our results suggest that the ac-
tivation of PKA by l-adrenaline depends on cAMP, which inhibits 
caspase-11 activity and IL-1 release in response to cytosolic LPS. In 
addition to the noncanonical inflammasome, cAMP can also shut 
down canonical inflammasome activation and restrain inflamma-
tion (30, 31). Recent studies have shown that the activation of PKA 
by bile acids or prostaglandin E2 inhibits NLRP3 inflammasome ac-
tivation through directly phosphorylating NLRP3 in macrophages 
(32, 33). PKA phosphorylates numerous metabolic enzymes, which 
may provide further feedback control of inflammasome activation 
(34). We found that PKA can bind caspase-11 to promote caspase-11 
phosphorylation, which may contribute to the inhibition of caspase-11 
activation. RAPGEF3, but not PKA, is required for cAMP-mediated 
NLRP3 inflammasome inhibition in endothelial cells (35). Thus, dis-
tinct, perhaps cell type–specific cAMP effector molecules may con-
tribute to the regulation of inflammasome.
In summary, our in vitro results demonstrate that l-adrenaline 
inhibits caspase-11 inflammasome activation through the ADRA2B 
receptor and the intracellular cAMP metabolism pathway in mouse 
macrophages or human monocytes. Our in vivo data confirm that tar-
geting the ADRA2B-ADCY4-PDE8A-PKA axis blocks the caspase-11–
mediated inflammatory response and tissue injury in septic mice. 
Thus, increasing cAMP levels in relevant immune cell subsets may 
provide an effective metabolism-based therapy for the treatment of 
lethal infection. Notably, the PKA signaling involved the associa-
tion of PKA with a family of scaffolding proteins termed A kinase–
anchoring proteins (AKAPs), which included 70 functionally distinct 
members (36). It remains of great interest to know which classes of 
AKAP can modulate PKA activity in the inhibition of caspase-11 
activation in the future.
MATERIALS AND METHODS
Reagents are described in table S1.
Cell culture and bacterial infection
The THP1 (no. TIB-202) cell line was obtained from the American 
Type Culture Collection (ATCC). Immortalized BMDMs from wild- 
type, Nlrp3−/−, Nlrc4−/−, and Nlrp1−/− mice were a gift from K. Fitzgerald 
(University of Massachusetts Medical School). BMDMs from Casp11−/− 
mice were obtained using 30% L929 cell–conditioned medium as a 
source of granulocyte/macrophage colony stimulating factor. CRISPR- 
Cas9–mediated Gsdmd−/− BMDMs were a gift from D. Abbott (Case 
Western Reserve University). Human peripheral blood monocytes 
were obtained from STEMCELL Technologies (no. 70034). These 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
no. 11995073, Thermo Fisher Scientific) supplemented with 10% 
heat-inactivated fetal bovine serum (no. TMS-013-B, Millipore) and 
1% penicillin and streptomycin (no. 15070-063, Thermo Fisher Sci-
entific) at 37°C, 95% humidity, and 5% CO2. Cells were primed with 
LPS (200 ng/ml, 6 hours), poly(I:C) (5 g/ml, 6 hours), or Pam3CSK4 
(1 g/ml, 6 hours) and then stimulated with LPS electroporation 
(1 g, 16 hours) or E. coli [multiplicity of infection (MOI), 25; 16 hours] 
infection (5, 37, 38). All cells used were authenticated using short 
tandem repeat (STR) profiling, and mycoplasma testing was negative.
E. coli (no. 11775) was obtained from the ATCC and then added 
to cells at an MOI of 25 in medium without antibiotics. After 30 min, 
cells were washed and incubated for 1.5 hours at 37°C in fresh 
medium supplemented with gentamicin (100 g/ml; no. G1397, 
Sigma-Aldrich) to kill extracellular bacteria.
Animal model of septic shock
We conducted all animal care and experiments in accordance with 
the Association for Assessment and Accreditation of Laboratory 
Animal Care guidelines (www.aaalac.org) and with approval from 
our institutional animal care and use committee. Mice were housed 
with their littermates in groups of four or five animals per cage and 
kept on a regular 12-hour light and dark cycle in a specific pathogen- 
free barrier facility.
GsdmdI105N/I105N mice (C57BL/6) were a gift from V. M. Dixit 
(Genentech Inc.). Casp11−/− mice (C57BL/6) were a gift from T. R. Billiar 
(University of Pittsburgh). Tlr4−/− (C57BL/6, no. 007227) mice were 
obtained from the Jackson Laboratory.
Septic shock was induced in male or female C57BL/6 mice (8 to 
10 weeks old, 22- to 26-g body weight). These mice were primed with 
poly(I:C) [10 mg/kg, ip (intraperitoneally)] and then challenged 
6 hours later with LPS (2 mg/kg, ip) (7). At 30 min, before the second 
LPS injection, mice were subcutaneously injected with inhibitors 
[l-adrenaline (2 mg/kg, ip), 8-Br-cAMP (10 mg/kg, ip), PF-04957325 
(5 mg/kg, ip), prednisolone (5 mg/kg, ip), quinapril (30 mg/kg, ip), 
or levosulpiride (20 mg/kg, ip)]. For each of the next 2 days, these 
inhibitors were injected at 12-hour intervals.
For starvation, mice were placed in clean cages without food for 
48 hours. Water was given ad libitum. After starvation, these mice 
were primed with poly(I:C) (10 mg/kg, ip) and then challenged 
6 hours later with LPS (2 mg/kg, ip under normal diet.
Cell viability assay
Cells were seeded into 96-well plates and incubated with the indi-
cated treatments. Subsequently, 100 l of fresh medium was added 
to cells containing 10 l of Cell Counting Kit-8 (CCK-8) solutions 
(CK04, Dojindo Laboratories) and incubated for 2 hours (37°C, 5% 
CO2). Absorbance at 450 nm was measured using a microplate from 
BioTek.
Biochemical assay
Commercially available enzyme-linked immunosorbent assay kits 
were used to measure the concentrations or activity of HMGB1 
(no. ST51011, Shino-Test Corporation), IL-1 (no. MLB00C or 
no. DLB50, R&D Systems), IL-18 (no. 7625, R&D Systems), LDH 
(no. ab102526, Abcam), IL-6 (no. M6000B, R&D Systems), TNF 
(no. MTA00B, R&D Systems), cAMP (no. ADI-901-067, Enzo Life 
Sciences), and PKA (no. ab139435, Abcam) in indicated samples. 
Measurement of serum tissue enzymes (CK, BUN, and ALT) was 
performed using the IDEXX Catalyst Dx Chemistry Analyzer.
LPS transfection
To stimulate caspase-11 noncanonical inflammasome activation, 
LPS was electroporated into indicated cells using the Neon Trans-
fection System (Thermo Fisher Scientific) according to the manu-
facturer’s protocol. Briefly, BMDMs were electroporated with LPS 
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(1 to 3 g) in buffer R (no. MPK10025, Thermo Fisher Scientific) 
under pulse voltage of 1400 V, pulse width of 10 ms, and pulse 
number 2 (5).
RNA interference
ON-TARGETplus SMARTpool siRNAs against indicated genes as 
described in table S1 were purchased from Dharmacon. This pool was 
a mixture of four siRNAs provided as a single reagent. The Neon 
Electroporation System from Invitrogen was used to deliver siRNAs 
into BMDMs. Transfected cells were recovered in complete DMEM. 
The medium was replaced at 3 hours after electroporation. The cells 
were cultured for 48 hours before further examination.
Western blot
Western blot was used to analyze protein expression as described 
previously (39). Briefly, after extraction, proteins in cell lysates were 
first resolved by 4 to 12% Criterion XT bis-tris gel electrophoresis 
and then transferred to a polyvinylidene difluoride membrane and 
subsequently incubated with the primary antibody (1:500 to 1:1000). 
After incubation with peroxidase-conjugated secondary antibodies 
(1:1000 to 1:2000), the signals were visualized by enhanced chemi-
luminescence (no. 32106, Thermo Fisher Scientific) according to the 
manufacturer’s instructions.
Quantitative real-time polymerase chain reaction
Total RNA was extracted using TRI reagent (no. 93289, Sigma-Aldrich) 
according to the manufacturer’s instructions. First-strand comple-
mentary DNA (cDNA) was synthesized from 1 g of RNA using the 
iScript cDNA Synthesis Kit (no. 1708890, Bio-Rad). cDNA from var-
ious cell samples was amplified using real-time qPCR with specific 
primers as described in table S1. The data were normalized to 18S 
RNA, and the fold change was calculated via the 2−Ct method (40). 
Relative concentrations of mRNA were expressed in arbitrary units 
based on the untreated group, which was assigned a value of 1.
Immunoprecipitation analysis
Cells were lysed at 4°C in ice-cold radioimmunoprecipitation assay 
lysis buffer, and cell lysates were cleared by brief centrifugation 
(12,000g for 10 min). Concentrations of proteins in the supernatant 
were determined by bicinchoninic acid (BCA) assay. Before immu-
noprecipitation, samples containing equal amounts of proteins were 
precleared with protein G agarose (4°C for 3 hours) and subsequently 
incubated with various irrelevant immunoglobulin G or anti–caspase-11 
antibodies (4 g/ml) in the presence of protein G agarose beads for 
2 hours or overnight at 4°C with gentle shaking. Following incuba-
tion, agarose beads were washed extensively with phosphate-buffered 
saline, and proteins were eluted by boiling in 2× SDS sample buffer 
before SDS–polyacrylamide gel electrophoresis for measurement of 
caspase-11, PRKACA, or p-Ser.
Statistical analysis
Data are presented as means ± SD. All data meet the assumptions of 
the tests (e.g., normal distribution). Unpaired Student’s t tests were 
used to compare the means of two groups. One-way analysis of vari-
ance (ANOVA) was used for comparison among the different groups. 
When ANOVA was significant, post hoc testing of differences be-
tween groups was performed using the least significant difference 
test. The Kaplan-Meier method was used to compare differences in 
mortality rates between groups. A P < 0.05 was considered statisti-
cally significant. The exact value of n within figures was indicated in 
the figure legends. We did not exclude samples or animals. For every 
figure, statistical tests are justified as appropriate. All data meet the 
assumptions of the tests. No statistical methods were used to prede-
termine sample sizes, but our sample sizes are similar to those gen-
erally used in the field.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/5/eaav5562/DC1
Fig. S1. Effects of l-adrenaline on cytosolic LPS-induced pyroptosis in human primary 
monocytes.
Fig. S2. Effects of l-adrenaline on LPS priming in BMDMs.
Fig. S3. Effects of l-adrenaline and PF-04957325 on serum cAMP level in mice with endotoxic 
shock.
Fig. S4. Effects of acute starvation-induced stress on endotoxic shock.
Fig. S5. Schematic summary of cAMP metabolism in the regulation of cytosolic LPS-induced 
caspase-11 inflammasome activation and pyroptosis.
Table S1. Reagent sources.
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